Fred Hutchinson Cancer Center is an independent, nonprofit organization providing adult cancer treatment and groundbreaking research focused on cancer and infectious diseases. Based in Seattle, Fred Hutch is the only National Cancer Institute-designated cancer center in Washington.
With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has earned a reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and network affiliations with hospitals in five states. Together, our fully integrated research and clinical care teams seek to discover new cures to the world’s deadliest diseases and make life beyond cancer a reality.
At Fred Hutch we value collaboration, compassion, determination, excellence, innovation, integrity and respect. These values are grounded in and expressed through the principles of diversity, equity and inclusion. Our mission is directly tied to the humanity, dignity and inherent value of each employee, patient, community member and supporter. Our commitment to learning across our differences and similarities make us stronger. We seek employees who bring different and innovative ways of seeing the world and solving problems. Fred Hutch is in pursuit of becoming an anti-racist organization. We are committed to ensuring that all candidates hired share our commitment to diversity, anti-racism and inclusion.
The Nabet laboratory is seeking a bright and highly motivated Research Technician I or II to provide high-level technical support for ongoing research efforts. The goals of our research program are to develop strategies to target cancer drivers by controlling protein stability and activity. We aim to gain new biological insights into clinically relevant targets and to advance new therapeutic strategies in cancer. We pioneered chemical biology technologies including the dTAG system to rapidly eliminate target proteins for therapeutic target discovery and validation (Nabet et al., Nature Chemical Biology 2018; Nabet et al., Nature Communications 2020). We are also highly collaborative and work to develop inhibitors and degraders for cancer drug targets (Koide et al., ChemBioChem 2023; Li et al., European Journal of Medicinal Chemistry 2022). The Nabet laboratory is committed to supporting the next-generation of scientists and believe in collaborative science (Nabet, ChemBioChem 2021). This is an exceptional opportunity to join a new team that is pushing the boundaries of cancer chemical biology.
We are seeking candidates to contribute to both conceptual and technical aspects of the project with the ability to work independently and part of a dynamic team. The candidate will develop engineered cancer model systems and evaluate small molecules in these models as well as assist in lab managerial duties including the set-up, operation and maintenance of laboratory instruments and equipment. The candidate will become involved with all the steps of research being completed by the group and will have the opportunity to present their research during meetings and be involved in the publishing of scientific abstracts and papers. The experience gained in the laboratory will be useful for pursuing diverse careers including those as a researcher or physician.
Fred Hutch offers great benefits and highly competitive salaries commensurate with experience.
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js');
fbq('init', '3151876674868105');
fbq('track', 'PageView');
Source link